What is the EURAMOS (European and American Osteosarcoma Study Group) protocol for treating osteosarcoma?

EURAMOS Protocol for Osteosarcoma

The EURAMOS (European and American Osteosarcoma Study) protocol is a standardized chemotherapy regimen for high-grade osteosarcoma consisting of preoperative MAP (methotrexate, doxorubicin/Adriamycin, and cisplatin) followed by surgery and risk-adapted postoperative chemotherapy based on histologic response to neoadjuvant treatment. 1, 2

Protocol Structure

Preoperative Phase

• Two 5-week cycles of MAP chemotherapy administered before surgery 1:
  • Methotrexate 12 g/m² × 2 doses per cycle
  • Doxorubicin 75 mg/m²
  • Cisplatin 120 mg/m²
• This preoperative phase totals 10 weeks of treatment 3
• Repeat imaging using the same modalities as baseline should be performed to reassess tumor resectability 4

Surgical Phase

• Wide excision with complete tumor resection is performed after neoadjuvant chemotherapy 4
• Histologic response is assessed by measuring the percentage of tumor necrosis in the resected specimen 1, 2

Risk Stratification Based on Histologic Response

Good Responders (≥90% or <10% viable tumor):

• These patients demonstrate favorable response to preoperative chemotherapy 1, 5
• Continue with MAP chemotherapy postoperatively (two additional cycles of MAP plus two cycles of MA - methotrexate and doxorubicin only) 1
• The EURAMOS-1 trial showed that adding pegylated interferon-α-2b to MAP did not improve outcomes, so this is not recommended 4
• 5-year overall survival for good responders: 88.8% and event-free survival: 81.4% 5

Poor Responders (<90% or ≥10% viable tumor):

• These patients have inadequate response to initial chemotherapy 1, 5
• Either continue MAP or switch to MAPIE (MAP plus ifosfamide and etoposide) 4, 1
• However, the EURAMOS-1 trial demonstrated that adding ifosfamide and etoposide (MAPIE) did not improve event-free survival compared to continuing MAP alone 4
• 5-year overall survival for poor responders: 66.5% and event-free survival: 31.4% 5

Key Trial Results

The EURAMOS-1 study represents the largest international collaboration in osteosarcoma research 1, 3:

• 2,260 patients registered from 326 centers across 17 countries between March 2005 and June 2011 1, 2
• 1,334 patients (59%) were randomized after surgery 1
• Median follow-up of 54 months 2

Overall Survival Outcomes

• 3-year event-free survival: 59% and 5-year event-free survival: 54% for all registered patients 2
• 3-year overall survival: 79% and 5-year overall survival: 71% 2
• Preoperative chemotherapy was completed according to protocol in 94% of patients 1

Toxicity Profile

Hematologic toxicity is substantial 1:

• Grade 3-4 neutropenia occurred in 83% of chemotherapy cycles
• 59% of cycles were complicated by infection
• Mortality related to preoperative chemotherapy was 0.13% (3 deaths in 2,260 patients)

Prognostic Factors

Adverse prognostic factors at diagnosis include 2:

• Pulmonary metastases (hazard ratio 2.34)
• Non-pulmonary metastases (hazard ratio 1.94)
• Axial skeleton tumor site (hazard ratio 1.53)

Favorable prognostic factors include 2:

• Telangiectatic histologic subtype (hazard ratio 0.52)
• Unspecified conventional subtype (hazard ratio 0.67) compared to chondroblastic subtype

For patients with localized disease in complete remission after surgery, poor histologic response was associated with significantly worse outcome (hazard ratio 2.13) 2

Management of Positive Margins

Surgical re-excision with or without radiation therapy should be considered for positive surgical margins 4:

• Combined photon/proton or proton beam radiation has shown effectiveness for local control in unresectable or incompletely resected osteosarcoma 4
• In head and neck osteosarcoma specifically, combined surgery and radiation improved local control and overall survival compared to surgery alone for patients with positive or uncertain margins 4

Clinical Application

This protocol is recommended for 4:

• High-grade osteosarcoma (category 1 recommendation for neoadjuvant chemotherapy)
• Patients aged ≤40 years with resectable disease
• Primary metastatic osteosarcoma patients treated with curative intent following the same principles

The protocol should NOT be used for 4:

• Low-grade central and parosteal osteosarcoma (surgery alone is sufficient)

Critical Pitfall

The major limitation identified by EURAMOS-1 is that modifying adjuvant chemotherapy based on histologic response does not improve outcomes for poor responders 4. Despite this finding, histologic response remains the strongest predictor of prognosis and should guide patient counseling and surveillance intensity 2, 5.